Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] A positive randomised trial in cutaneous T-cell lymphoma

The discovery that CD30 (Ki-1, TNFRSF8), a membrane protein belonging to the tumour necrosis factor receptor superfamily, is uniformly expressed in anaplastic large-cell lymphoma was instrumental in defining CD30-positive T-cell lymphoproliferative disorders.1 Less homogeneous expression of CD30 was also reported in cutaneous T-cell lymphoma, particularly in tumour-stage mycosis fungoides with large-cell transformation.2 Attempts to therapeutically target CD30 with SGN-30 (cAC10), a so-called naked chimeric anti-CD30 monoclonal antibody, were disappointing,3 with the exception of a small study4 in cutaneous T-cell lymphoma, which showed 16 (70%) of 23 patients achieving an overall response, with some durable complete responses.

email